$NVLX After presenting the results of its large scale Phase III clinical trial at the 2013 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology in late January, the U.S. Food and Drug Administration (FDA) moved quickly to approve Celgene Corp.'s ABRAXANE® when used in combination with gemcitabine.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.